Showing results (811-820 of 834) with videos related to

Sort By:
Pageof 84
JAMA|December 17, 2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew A Kanner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205Rimas V Lukas, Lijie Zhai, Kristen L Lauing, et al.
The Journal of Clinical Investigation|June 28, 2024
STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastomaHinda Najem, Spencer T Lea, Shashwat Tripathi, et al.
AJNR. American Journal of Neuroradiology|June 26, 2024
A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in AdultsBenjamin M Ellingson, Francesco Sanvito, Timothy F Cloughesy, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2012
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modalityRoger Stupp, Eric T Wong, Andrew A Kanner, et al.
The Oncologist|January 22, 2026
Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysisOgechukwu A Asogwa, Linda Dirven, Neil K Aaronson, et al.
Neuro-Oncology|July 19, 2024
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomasKwang-Soo Kim, Karl Habashy, Andrew Gould, et al.
Nature Communications|June 6, 2024
Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomasVíctor A Arrieta, Andrew Gould, Kwang-Soo Kim, et al.
Neuro-Oncology|January 26, 2026
Integrated immune profiling of chordomas reveals spatially organized niches and functional heterogeneityVictor A Arrieta, J Kada Benotmane, Rebecca Du, et al.
The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.
Pageof 84